Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3–Targeted Single-Domain Antibody PET

We successfully designed, engineered, and tested a GPC3-targeted 18F-labeled nanobody immunoPET agent, Al[18F]F-ssHN3, demonstrating that it can be used for same-day diagnostic imaging in murine models of liver cancer. Importantly, this agent could address the limitations of current imaging methods by detecting residual disease after thermal ablation and other locoregional therapies.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-10-17
DOI
https://doi.org/10.1158/1078-0432.ccr-25-2587
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3–Targeted Single-Domain Antibody PET

Stanley Fayn, Ross W. Cheloha, Jesse Buffington, Bradford J. Wood et al.
Clinical Cancer Research
Monoclonal and Polyclonal Antibodies Research
article

Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3–Targeted Single-Domain Antibody PET

Stanley Fayn, Ross W. Cheloha, Jesse Buffington, Bradford J. Wood, Joon‐Yong Chung, Mitchell Ho, Orit Jacobson, Falguni Basuli, Hima Makala, Jianfeng Shi, Rolf E. Swenson, Colleen P. Olkowski, Freddy E. Escorcia, Peter L. Choyke, Robert Morhard, Dan Li, Woong Hee Lee, Divya Nambiar
article en

Abstract

We successfully designed, engineered, and tested a GPC3-targeted 18F-labeled nanobody immunoPET agent, Al[18F]F-ssHN3, demonstrating that it can be used for same-day diagnostic imaging in murine models of liver cancer. Importantly, this agent could address the limitations of current imaging methods by detecting residual disease after thermal ablation and other locoregional therapies.

Clinical Cancer ResearchVol. 31(24)
National Institutes of Health (US), National Institute of Diabetes and Digestive and Kidney Diseases (US), CRUK/MRC Oxford Institute for Radiation Oncology (GB), National Heart, Lung, and Blood Institute (US), National Cancer Institute (UA), Frederick National Laboratory for Cancer Research (US), National Cancer Institute (US), Center for Cancer Research (US)
Openalex Percentile: Top 57%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.